Evaluation of metabolic labeling for comparative proteomics in breast cancer cells.
暂无分享,去创建一个
[1] F. Regnier,et al. Minimizing resolution of isotopically coded peptides in comparative proteomics. , 2002, Journal of proteome research.
[2] A. Tulpule,et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. , 1986, The Journal of biological chemistry.
[3] F. Regnier,et al. Global internal standard technology for comparative proteomics. , 2002, Journal of chromatography. A.
[4] K. Hemminki,et al. Re: markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. , 2000, Journal of the National Cancer Institute.
[5] C. Swanson,et al. Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. , 1993, British Journal of Cancer.
[6] A. English,et al. Quantitative analysis of the yeast proteome by incorporation of isotopically labeled leucine. , 2002, Journal of proteome research.
[7] Y. Hathout,et al. Differential protein expression in the cytosol fraction of an MCF-7 breast cancer cell line selected for resistance toward melphalan. , 2002, Journal of proteome research.
[8] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[9] Y. Hathout,et al. Proteomic phenotyping: metastatic and invasive breast cancer. , 2004, Cancer letters.
[10] D. Scudiero,et al. Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. , 1998, Journal of the National Cancer Institute.
[11] A. Multani,et al. Multidrug-resistant MCF-7 cells: an identity crisis? , 2002, Journal of the National Cancer Institute.